(Albany, US) DelveInsight has launched a new report on Progressive Supranuclear Palsy Market Insights, Epidemiology, and Market Forecast-2030.DelveInsight’s ‘ Progressive Supranuclear Palsy Market Insights, Epidemiology, and Market Forecast-2030’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Progressive Supranuclear Palsy in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.Some of Progressive Supranuclear Palsy facts:According to Delveinsight, prevalence of PSP was 1.89 per 100,000 and age-standardized prevalence to the US population was 2.95 per 100,000.DelveInsight’s Analysts, estimated that the prevalence of PSP in the UK was 1.0 per 100,000.
The age-adjusted standardized prevalence figure for PSP from this study was observed to be 5.0.According to a study conducted by Kawashima et al.
2004, in Japan the prevalence of PSP was 5.82 per 100,000United States has the highest percentage of prevalent diagnosed and treated patientsRequest for free Sample Report: https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-marketView Report: https://www.delveinsight.com/report-store/progressive-supranuclear-palsy-marketScope of Progressive Supranuclear Palsy Report:The report covers the descriptive overview of Progressive Supranuclear Palsy , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapiesComprehensive insight has been provided into the Progressive Supranuclear Palsy epidemiology and treatment in the 7MMAdditionally, an all-inclusive account of both the current and emerging therapies for Progressive Supranuclear Palsy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscapeA detailed review of Progressive Supranuclear Palsy market; historical and forecasted is included in the report, covering drug outreach in the 7MMThe report provides an edge while developing business strategies, by understanding trends shaping and driving the global Progressive Supranuclear Palsy marketRequest for free Sample Report: https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-marketView Report: https://www.delveinsight.com/report-store/progressive-supranuclear-palsy-marketProgressive Supranuclear Palsy (PSP) is a rare progressive condition that can cause problems with balance, movement, vision, speech and swallowing.The condition has been linked to changes in certain genes, but these genetic faults are not inherited and the risk to other family members (including the children or siblings) with PSP, is very low.
Although PSP is not fatal, symptoms do continue to worsen and it can not be cured.Complications that result from worsening symptoms, such as pneumonia (from breathing in food particles while choking during eating) can be life threatening.
There are different subtypes of PSP which incudes, PSP with Richardson’s syndrome (PSP-RS), PSP with predominant parkinsonism (PSP-P), PSP with pure akinesia with gait freezing (PSP- PAGF), PSP with corticobasal syndrome (PSP-CBS), PSP with predominant language and speech dysfunction (PSP-PNFA and PSP-AOS), PSP with predominant frontotemporal dysfunction (PSP-FTD), PSP with cerebellar ataxia (PSP-C), and PSP with primary lateral sclerosis (PSP-PLS).The only proven risk factor for PSP is age.
The condition typically affects people around the age of 60, and is virtually unknown in people under the age of 40.There's no single test for PSP.